RIGL
Income statement / Annual
Last year (2023), Rigel Pharmaceuticals, Inc.'s total revenue was $116.88 M,
a decrease of 2.79% from the previous year.
In 2023, Rigel Pharmaceuticals, Inc.'s net income was -$25.09 M.
See Rigel Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$116.88 M
|
$120.24 M
|
$149.24 M
|
$108.62 M
|
$59.29 M
|
$44.51 M
|
$4.48 M
|
$20.38 M
|
$28.90 M
|
$8.25 M
|
| Cost of Revenue |
$7.11 M |
$1.75 M |
$1.08 M |
$895,000.00 |
$906,000.00 |
$287,000.00 |
$46.27 M |
$63.45 M |
$62.83 M |
$67.70 M |
| Gross Profit |
$109.77 M |
$118.49 M |
$148.15 M |
$107.73 M |
$58.38 M |
$44.22 M |
-$41.79 M |
-$43.06 M |
-$33.93 M |
-$59.45 M |
| Gross Profit Ratio |
0.94 |
0.99 |
0.99 |
0.99 |
0.98 |
0.99 |
-9.32 |
-2.11 |
-1.17 |
-7.21 |
| Research and Development
Expenses |
$24.52 M
|
$60.27 M
|
$65.24 M
|
$60.10 M
|
$52.89 M
|
$46.90 M
|
$46.27 M
|
$63.45 M
|
$62.83 M
|
$67.70 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$70.00 M
|
$37.83 M
|
$20.91 M
|
$17.81 M
|
$31.80 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$105.74 M
|
$112.45 M
|
$91.89 M
|
$76.60 M
|
$74.59 M
|
$70.00 M
|
$37.83 M
|
$20.91 M
|
$17.81 M
|
$31.80 M
|
| Other Expenses |
$0.00 |
$1.32 M |
$3.52 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$130.26 M |
$172.72 M |
$157.13 M |
$136.70 M |
$127.47 M |
$116.91 M |
$84.10 M |
$84.35 M |
$80.64 M |
$99.50 M |
| Cost And Expenses |
$137.37 M |
$174.47 M |
$158.21 M |
$137.59 M |
$128.38 M |
$117.19 M |
$84.10 M |
$84.35 M |
$80.64 M |
$99.50 M |
| Interest Income |
$2.27 M |
$684,000.00 |
$47,000.00 |
$582,000.00 |
$2.53 M |
$2.20 M |
$892,000.00 |
$437,000.00 |
$222,000.00 |
$243,000.00 |
| Interest Expense |
$6.87 M |
$3.71 M |
$4.86 M |
$1.35 M |
$335,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.24 M
|
$998,000.00
|
$1.16 M
|
$706,000.00
|
$683,000.00
|
$594,000.00
|
$465,000.00
|
$941,000.00
|
$1.44 M
|
$2.36 M
|
| EBITDA |
-$16.98 M
|
-$53.87 M
|
-$11.29 M
|
-$27.69 M
|
-$65.88 M
|
-$69.89 M
|
-$77.53 M
|
-$63.03 M
|
-$50.30 M
|
-$88.89 M
|
| EBITDA Ratio |
-0.15 |
-0.45 |
-0.06 |
-0.26 |
-1.12 |
-1.63 |
-17.92 |
-2.86 |
-1.79 |
-11.07 |
| Operating Income Ratio
|
-0.18
|
-0.45
|
-0.06
|
-0.27
|
-1.17
|
-1.63
|
-17.76
|
-3.42
|
-1.79
|
-11.06
|
| Total Other
Income/Expenses Net |
-$4.60 M
|
-$3.02 M
|
-$4.81 M
|
-$771,000.00
|
$2.20 M
|
$2.20 M
|
$1.62 M
|
$525,000.00
|
$279,000.00
|
$341,000.00
|
| Income Before Tax |
-$25.09 M |
-$58.57 M |
-$17.31 M |
-$29.74 M |
-$66.89 M |
-$70.48 M |
-$77.99 M |
-$69.22 M |
-$51.46 M |
-$90.91 M |
| Income Before Tax Ratio
|
-0.21
|
-0.49
|
-0.12
|
-0.27
|
-1.13
|
-1.58
|
-17.39
|
-3.4
|
-1.78
|
-11.02
|
| Income Tax Expense |
$0.00 |
$3.02 M |
$605,000.00 |
$647,000.00 |
-$348,000.00 |
$2.20 M |
-$2.09 M |
$4.30 M |
-$1.72 M |
-$2.70 M |
| Net Income |
-$25.09 M |
-$61.60 M |
-$17.91 M |
-$30.39 M |
-$66.55 M |
-$70.48 M |
-$77.99 M |
-$69.22 M |
-$51.46 M |
-$90.91 M |
| Net Income Ratio |
-0.21 |
-0.51 |
-0.12 |
-0.28 |
-1.12 |
-1.58 |
-17.39 |
-3.4 |
-1.78 |
-11.02 |
| EPS |
-1.44 |
-3.4 |
-1.05 |
-1.76 |
-4 |
-4.39 |
-6.17 |
-7.33 |
-5.82 |
-10.37 |
| EPS Diluted |
-1.44 |
-3.4 |
-1.05 |
-1.76 |
-4 |
-4.39 |
-6.17 |
-7.33 |
-5.82 |
-10.37 |
| Weighted Average Shares
Out |
$17.40 M
|
$17.24 M
|
$17.05 M
|
$16.88 M
|
$16.72 M
|
$16.05 M
|
$12.63 M
|
$9.44 M
|
$8.84 M
|
$8.77 M
|
| Weighted Average Shares
Out Diluted |
$17.40 M
|
$17.24 M
|
$17.05 M
|
$16.88 M
|
$16.74 M
|
$16.05 M
|
$12.63 M
|
$9.44 M
|
$8.84 M
|
$8.77 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
